Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
ErythroMer is a red blood cell substitute in development by KaloCyte, supported with funding by the National Institutes of Health, U.S. Department of Defense, and private investment. Similar to other hemoglobin-based oxygen carriers, the product is stable for several months even when freeze-dried. It can be reconstituted from this lyophilized state in emergencies. This opens up the possibility of eventual stockpiling of ErythroMer, making it easier to supply blood in large amounts to those who need it. The development of this technology was done at Washington University in St. Louis and University of Illinois Urbana-Champaign. Trials have been successful in rats, mice, and rabbits, and human trials are planned. ErythroMer is a reddish blood powder composed of hemoglobin from humans. By coating it with a synthetic polymer, it can sense pH changes, allowing for oxygen pick up in areas where the pH levels are high and disposal where they are low. In the spring of 2024, ErythroMer showed promise in pre-clinical testing. In animal testing, it effectively delivered oxygen and helped revive animals with significant blood loss. In 2025, KaloCyte announced a licensing agreement with Chrysea for ErythroMer production.
Whey Protein: 96 Whole Soy Bean: 96 Human milk: 95 Chicken egg: 94 Soybean milk: 91 Buckwheat: 90+ Cow milk: 90 Cheese: 84 Quinoa: 83 Rice: 83 Defatted soy flour: 81 Fish: 76 Beef: 74 Immature bean: 65 Full-fat soy flour: 64 Soybean curd (tofu): 64 Whole wheat: 64 White flour: 41 Common foodstuffs and their values: (Note: These values use "whole egg" as a value of 100, so foodstuffs that provide even more nitrogen than whole eggs, can have a value of more than 100. 100, does not mean that 100% of the nitrogen in the food is incorporated into the body, and not excreted, as in other charts.)
=== Key organisations === Key figures in the early phases of the Vaal uprising in the Vaal Triangle area were the Vaal Civic Association VCA and the Congress of South African Students (COSAS). Both were affiliates of the UDF, a nationwide popular front of civic organisations which had been launched in August 1983 and which subsequently had played a leading role in boycotts of the 1984 general election. Some of the UDF's affiliates in black townships, notably in Atteridgeville, Kagiso, and Soweto, had organised local campaigns against the Koornhof Bills, and in 1983 the front had boasted that its involvement had contributed to low election turnouts at that year's council elections – though, according to Jeremy Seekings, its involvement was neither intensive nor well-organised. Most of the organisations at the forefront of the uprising considered themselves to be affiliates of the UDF, whether formally or informally. These included local civic associations as well as some national structures, such as the Release Mandela Committee. However, branches of the Azanian People's Organisation (AZAPO) were also involved in parts of the Cape Province and Transvaal, as were various unaffiliated and relatively autonomous groups, particularly militant youth groups, many of which were formed during the course of the uprising.
Sources: en.wikipedia.org
CIDP is a neurological disorder caused by an injury to the protective coating of the nerves as they leave the brain. However, this was almost immediately ruled out by his physicians as testing was already done against the possibility of CIDP. Leaving the paralysis to be a rare side effect of the clinical drug, Ibrutinib Joe was taking to control his blood cancer, only he hasn't been taking the medication since a blood clot almost killed him. Dr. Lisa Sanders suggests that his regaining feeling in his toes is a result of Joe being off the medication, as it could take up to a year for the medication to fully leave his body and for the nerves to rebuild themselves. This raises the issue that if Joe stays off the medication he might be able to walk again but if he doesn't get back on he will have nothing controlling his blood cancer. Dr. Lisa Sanders later published Ann’s story on the column and awaited the response from the audience. The audience presented with many possibilities but Ann’s doctors had tested and ruled them all out except for two. The first possibility is Lyme Disease which is an infection caused by bacteria transmitted through ticks. While Ann’s symptoms are not in line with that of Lyme Disease, the disease is known for causing all kinds of strange and interesting neurological problems. The second possibility is that Ann has a Functional Neurological Disorder, where simply her body is not transmitting the correct signals.
== Investments == Mubadala has invested in logistics software startup Turvo, Alphabet-owned self-driving technology company Waymo, Reliance Jio Platforms, UK life sciences company Envision, and Telegram. Mubadala is a parent company of GlobalFoundries, a semiconductor foundry company. Mubadala owns stakes in numerous companies, including a 7.5 percent share in the Carlyle Group. In 2007 Mubadala announced an initial investment in AMD. As of 2017 Mubadala had a stake of 12.9 percent in the chipmaker. In 2019 Mubadala sold its entire stake in AMD. In 2019, Mubadala and Falcon Edge Capital established Abu Dhabi Catalyst Partners, a $1 billion joint venture to invest in financial institutions. In November 2020, Mubadala transferred ownership of two information technology companies it previously owned, Injazat and Khazna, to artificial intelligence company, G42, and took a stake in G42. In 2021, Mubadala purchased a 2.6% stake in En+ Group, a manufacturer of green aluminum, from Polina Yumasheva, the former wife of Russian businessman Oleg Deripaska. The same year, Mubadala purchased MetrôRio, the company that holds the operations for the Rio de Janeiro metro, from Invepar. In 2016, Mubadala became the biggest external shareholder at Investcorp, after acquiring 20% stakes in the Bahraini firm. In 2023, a former UK minister, Gerry Grimstone was criticized for conducting and not declaring 13 meetings with Mubadala and Khaldoon al-Mubarak, after acquiring the role as an adviser and the chair of planned climate fund at Investcorp.
=== Thiol/disulfide chemistry === Glutathione reductase (GR) catalyzes the reduction of glutathione disulfide (GSSG) to glutathione (GSH). GR requires FAD and NADPH to facilitate this reaction; first a hydride must be transferred from NADPH to FAD. The reduced flavin can then act as a nucleophile to attack the disulfide, this forms the C4a-cysteine adduct. Elimination of this adduct results in a flavin-thiolate charge-transfer complex.
Sources: en.wikipedia.org
== Quality of living == Bangkok was ranked 129th of 230 (1=best quality of living, 230=worst quality of living) cities worldwide in Mercer's 2016 Quality of Living survey rankings. Vienna was ranked number 1, Baghdad last. Singapore (26) is the highest-ranked Asian city. Behind Singapore, the second highest-ranked city in Southeast Asia is Kuala Lumpur (86). Manila is ranked 136 and Jakarta 142. On the "personal safety" component of the ranking, Bangkok was ranked 173rd, due to political unrest and terrorist attacks.
Numerous species of hagfish feed on carrion, including Atlantic hagfish, black hagfish, blueband hagfish, Pacific hagfish, slender hagfish and whiteface hagfish. Types of carrion eaten include dead whales, hake, mackerel, pilchards and jellyfish, as well as fishery discards of whiting and langoustine. Hagfish are highly adapted to carrion feeding. For example, they are able to survive extended periods without eating and can detect carrion from long distances. Hagfish are also highly mobile and can arrive at carcasses within minutes or hours of an animal’s death. Immune defenses such as lysozyme-containing slime and antimicrobial proteins (e.g. myxinidin) are thought to protect hagfish from microbial pathogens.
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-alanine:NAD+ oxidoreductase (deaminating). Other names in common use include AlaDH, L-alanine dehydrogenase, NAD+-linked alanine dehydrogenase, alpha-alanine dehydrogenase, NAD+-dependent alanine dehydrogenase, alanine oxidoreductase, and NADH-dependent alanine dehydrogenase. T
The number of PPIs identified is usually low because of a high false negative rate; and, understates membrane proteins, for example. During his studies, Molecular biologist Anton Yuryev used yeast two-hybrid screening to identify novel protein interactions linking transcription with post‑transcriptional modification, demonstrating the utility of these methods for revealing functional, isoform‑specific PPIs. In initial studies that utilized Y2H, proper controls for false positives (e.g. when DB-X activates the reporter gene without the presence of AD-Y) were frequently not done, leading to a higher than normal false positive rate. An empirical framework must be implemented to control for these false positives. Limitations in lower coverage of membrane proteins have been overcoming by the emergence of yeast two-hybrid variants, such as the membrane yeast two-hybrid (MYTH) and the split-ubiquitin system, which are not limited to interactions that occur in the nucleus; and, the bacterial two-hybrid system, performed in bacteria;
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.